Verrica Pharmaceuticals Inc (OQ:VRCA)

May 27, 2020 07:30 am ET
Verrica Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually...
May 07, 2020 07:00 am ET
Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31,...
May 06, 2020 07:05 am ET
Verrica Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually...
Apr 09, 2020 04:05 pm ET
Verrica Pharmaceuticals to Participate in the 19th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually...
Mar 13, 2020 07:00 am ET
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced financial results for the fourth quarter ended December 31,...
Mar 11, 2020 07:00 am ET
Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine loan and security...
Feb 20, 2020 09:45 am ET
Verrica Pharmaceuticals to Attend Several Upcoming Investor Conferences
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will attend...
Jan 29, 2020 07:00 am ET
Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the appointment of two new Vice Presidents in its...
Jan 18, 2020 10:00 am ET
Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced the presentation of positive data from a post-hoc pooled...
Nov 27, 2019 07:00 am ET
Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company, today announced that its New Drug Application (NDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum...
Nov 25, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Nov 19, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019. “Glenn was a renowned figure in...
Nov 06, 2019 04:05 pm ET
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
Oct 18, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > - Verrica Pharmaceuticals Inc. (“Verrica”)...
Oct 09, 2019 07:00 am ET
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced it...
Oct 07, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Leadership Team Update
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Sep 16, 2019 07:00 am ET
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Aug 28, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Aug 07, 2019 04:01 pm ET
Verrica Pharmaceuticals Reports Second Quarter 2019 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
Jun 27, 2019 04:01 pm ET
Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Jun 26, 2019 04:01 pm ET
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
May 21, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Participation in the Jefferies 2019 Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
May 07, 2019 04:01 pm ET
Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
May 01, 2019 07:47 am ET
Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that...
Mar 07, 2019 04:01 pm ET
Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced...
Mar 02, 2019 05:10 pm ET
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today presented data...
Feb 27, 2019 07:00 am ET
Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Feb 12, 2019 07:00 am ET
Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced that results from two...
Jan 07, 2019 07:00 am ET
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jan 03, 2019 06:30 am ET
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Nov 16, 2018 08:40 am ET
Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PlayAGS, Inc. (NYSE:AGS), BEST, Inc. Sponsored ADR (NYSE:BSTI), Verrica...
Nov 07, 2018 04:32 pm ET
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Nov 01, 2018 04:05 pm ET
Verrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Sep 24, 2018 07:05 am ET
Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® Indexes
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Sep 12, 2018 04:05 pm ET
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule
Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Aug 15, 2018 06:50 am ET
Verrica Appoints Neetu Dhaliwal as Vice President of Business Development
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Aug 07, 2018 04:01 pm ET
Verrica Reports Second Quarter 2018 Financial Results
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jun 19, 2018 04:05 pm ET
Verrica Pharmaceuticals Inc. Announces Closing of Initial Public Offering
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...
Jun 14, 2018 05:52 pm ET
Verrica Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today...